nodes	percent_of_prediction	percent_of_DWPC	metapath
Lumiracoxib—PTGS2—amyotrophic lateral sclerosis	0.617	1	CbGaD
Lumiracoxib—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.378	1	CbGbCtD
Lumiracoxib—Bromfenac—PTGS2—amyotrophic lateral sclerosis	0.00157	0.311	CrCbGaD
Lumiracoxib—Tolmetin—PTGS2—amyotrophic lateral sclerosis	0.00105	0.209	CrCbGaD
Lumiracoxib—Meclofenamic acid—PTGS2—amyotrophic lateral sclerosis	0.00104	0.206	CrCbGaD
Lumiracoxib—Mefenamic acid—PTGS2—amyotrophic lateral sclerosis	0.000806	0.16	CrCbGaD
Lumiracoxib—Diclofenac—PTGS2—amyotrophic lateral sclerosis	0.000579	0.115	CrCbGaD
Lumiracoxib—CYP2C19—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	6.87e-06	0.0312	CbGpPWpGaD
Lumiracoxib—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	6.76e-06	0.0307	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	6.3e-06	0.0286	CbGpPWpGaD
Lumiracoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—RAB5A—amyotrophic lateral sclerosis	6.17e-06	0.028	CbGpPWpGaD
Lumiracoxib—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	6.09e-06	0.0276	CbGpPWpGaD
Lumiracoxib—CYP1A2—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	5.35e-06	0.0243	CbGpPWpGaD
Lumiracoxib—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	4.49e-06	0.0204	CbGpPWpGaD
Lumiracoxib—PTGS1—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	3.85e-06	0.0174	CbGpPWpGaD
Lumiracoxib—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	3.84e-06	0.0174	CbGpPWpGaD
Lumiracoxib—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—amyotrophic lateral sclerosis	3.83e-06	0.0174	CbGpPWpGaD
Lumiracoxib—PTGS1—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	3.69e-06	0.0167	CbGpPWpGaD
Lumiracoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	3.38e-06	0.0153	CbGpPWpGaD
Lumiracoxib—UGT1A9—NRF2 pathway—GSR—amyotrophic lateral sclerosis	3.15e-06	0.0143	CbGpPWpGaD
Lumiracoxib—PTGS2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	3.05e-06	0.0139	CbGpPWpGaD
Lumiracoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	3.01e-06	0.0137	CbGpPWpGaD
Lumiracoxib—PTGS1—Overview of nanoparticle effects—PTGS2—amyotrophic lateral sclerosis	3e-06	0.0136	CbGpPWpGaD
Lumiracoxib—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	2.93e-06	0.0133	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	2.72e-06	0.0124	CbGpPWpGaD
Lumiracoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—amyotrophic lateral sclerosis	2.59e-06	0.0117	CbGpPWpGaD
Lumiracoxib—PTGS1—Eicosanoid Synthesis—PTGS2—amyotrophic lateral sclerosis	2.49e-06	0.0113	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	2.46e-06	0.0112	CbGpPWpGaD
Lumiracoxib—PTGS1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.45e-06	0.0111	CbGpPWpGaD
Lumiracoxib—UGT1A9—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	2.3e-06	0.0104	CbGpPWpGaD
Lumiracoxib—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	2.15e-06	0.00976	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	2.1e-06	0.00951	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	2.09e-06	0.0095	CbGpPWpGaD
Lumiracoxib—UGT1A9—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	2.08e-06	0.00945	CbGpPWpGaD
Lumiracoxib—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	2.08e-06	0.00944	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	2.01e-06	0.0091	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	1.98e-06	0.009	CbGpPWpGaD
Lumiracoxib—PTGS2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.95e-06	0.00883	CbGpPWpGaD
Lumiracoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	1.95e-06	0.00883	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	1.92e-06	0.0087	CbGpPWpGaD
Lumiracoxib—PTGS2—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	1.87e-06	0.0085	CbGpPWpGaD
Lumiracoxib—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	1.8e-06	0.00816	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	1.78e-06	0.00809	CbGpPWpGaD
Lumiracoxib—UGT1A9—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	1.78e-06	0.00806	CbGpPWpGaD
Lumiracoxib—PTGS1—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	1.74e-06	0.00789	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	1.71e-06	0.00775	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	1.71e-06	0.00774	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	1.68e-06	0.0076	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	1.56e-06	0.00709	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	1.45e-06	0.00659	CbGpPWpGaD
Lumiracoxib—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.41e-06	0.00641	CbGpPWpGaD
Lumiracoxib—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	1.4e-06	0.00636	CbGpPWpGaD
Lumiracoxib—UGT1A9—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	1.39e-06	0.0063	CbGpPWpGaD
Lumiracoxib—PTGS1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	1.38e-06	0.00627	CbGpPWpGaD
Lumiracoxib—PTGS2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	1.38e-06	0.00626	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	1.37e-06	0.0062	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	1.36e-06	0.00615	CbGpPWpGaD
Lumiracoxib—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.29e-06	0.00585	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	1.28e-06	0.0058	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	1.24e-06	0.00563	CbGpPWpGaD
Lumiracoxib—UGT1A9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.22e-06	0.00553	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.2e-06	0.00545	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	1.17e-06	0.00532	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	1.17e-06	0.00529	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	1.15e-06	0.00523	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.15e-06	0.00521	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	1.14e-06	0.00517	CbGpPWpGaD
Lumiracoxib—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.1e-06	0.005	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	1.08e-06	0.00492	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	1.07e-06	0.00486	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	1.03e-06	0.00465	CbGpPWpGaD
Lumiracoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	1.02e-06	0.00462	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	9.97e-07	0.00452	CbGpPWpGaD
Lumiracoxib—PTGS1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.93e-07	0.00451	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	9.85e-07	0.00447	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	9.36e-07	0.00425	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—VAPB—amyotrophic lateral sclerosis	9.33e-07	0.00424	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—TPK1—amyotrophic lateral sclerosis	9.33e-07	0.00424	CbGpPWpGaD
Lumiracoxib—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	9.24e-07	0.00419	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	9.01e-07	0.00409	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	8.98e-07	0.00408	CbGpPWpGaD
Lumiracoxib—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	8.79e-07	0.00399	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	8.7e-07	0.00395	CbGpPWpGaD
Lumiracoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	8.69e-07	0.00394	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—VAPA—amyotrophic lateral sclerosis	8.54e-07	0.00387	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	8.38e-07	0.0038	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	8.28e-07	0.00376	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	8.22e-07	0.00373	CbGpPWpGaD
Lumiracoxib—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	7.97e-07	0.00362	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.94e-07	0.0036	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	7.88e-07	0.00357	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	7.68e-07	0.00348	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	7.64e-07	0.00347	CbGpPWpGaD
Lumiracoxib—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	7.63e-07	0.00346	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	7.61e-07	0.00345	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	7.61e-07	0.00345	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—FIG4—amyotrophic lateral sclerosis	7.46e-07	0.00339	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.43e-07	0.00337	CbGpPWpGaD
Lumiracoxib—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	7.27e-07	0.0033	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	7.21e-07	0.00327	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	7.18e-07	0.00326	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.1e-07	0.00322	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	7.02e-07	0.00319	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.98e-07	0.00317	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.96e-07	0.00316	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	6.75e-07	0.00306	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	6.66e-07	0.00302	CbGpPWpGaD
Lumiracoxib—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	6.64e-07	0.00301	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	6.53e-07	0.00296	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.47e-07	0.00294	CbGpPWpGaD
Lumiracoxib—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	6.21e-07	0.00282	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.14e-07	0.00278	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	6.08e-07	0.00276	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	6.04e-07	0.00274	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	6.04e-07	0.00274	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	5.77e-07	0.00262	CbGpPWpGaD
Lumiracoxib—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.73e-07	0.0026	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.65e-07	0.00256	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.63e-07	0.00256	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	5.52e-07	0.00251	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	5.5e-07	0.0025	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.4e-07	0.00245	CbGpPWpGaD
Lumiracoxib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	5.23e-07	0.00237	CbGpPWpGaD
Lumiracoxib—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.22e-07	0.00237	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.15e-07	0.00234	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.14e-07	0.00233	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	5.12e-07	0.00233	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	5.11e-07	0.00232	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.92e-07	0.00223	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	4.84e-07	0.0022	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.83e-07	0.00219	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	4.72e-07	0.00214	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.53e-07	0.00205	CbGpPWpGaD
Lumiracoxib—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.46e-07	0.00202	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.4e-07	0.002	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	4.39e-07	0.00199	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	4.39e-07	0.00199	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	4.37e-07	0.00198	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	4.37e-07	0.00198	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.3e-07	0.00195	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.21e-07	0.00191	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	4.17e-07	0.00189	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.09e-07	0.00186	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	4.01e-07	0.00182	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	4e-07	0.00182	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	4e-07	0.00182	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	3.95e-07	0.00179	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	3.88e-07	0.00176	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	3.85e-07	0.00175	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.73e-07	0.00169	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.73e-07	0.00169	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	3.66e-07	0.00166	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.54e-07	0.0016	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	3.52e-07	0.0016	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	3.51e-07	0.00159	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.5e-07	0.00159	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.49e-07	0.00158	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	3.42e-07	0.00155	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	3.42e-07	0.00155	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.4e-07	0.00154	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.31e-07	0.0015	CbGpPWpGaD
Lumiracoxib—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	3.29e-07	0.00149	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	3.2e-07	0.00145	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.19e-07	0.00145	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	3.17e-07	0.00144	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.16e-07	0.00143	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	3.13e-07	0.00142	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	3.05e-07	0.00139	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.96e-07	0.00134	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.91e-07	0.00132	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.89e-07	0.00131	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.88e-07	0.00131	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.78e-07	0.00126	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.73e-07	0.00124	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	2.53e-07	0.00115	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.51e-07	0.00114	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.47e-07	0.00112	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.42e-07	0.0011	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2.4e-07	0.00109	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.29e-07	0.00104	CbGpPWpGaD
Lumiracoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.24e-07	0.00101	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	2.22e-07	0.00101	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	2.19e-07	0.000994	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.08e-07	0.000945	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	2.02e-07	0.000918	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.02e-07	0.000917	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.98e-07	0.000896	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.91e-07	0.000869	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.87e-07	0.00085	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.84e-07	0.000836	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	1.84e-07	0.000834	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.82e-07	0.000827	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.73e-07	0.000784	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.7e-07	0.000771	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.66e-07	0.000754	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.66e-07	0.000754	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	1.58e-07	0.000715	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.57e-07	0.000714	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	1.57e-07	0.000714	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.56e-07	0.000708	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.52e-07	0.000688	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.42e-07	0.000644	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.35e-07	0.000612	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.3e-07	0.000588	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.28e-07	0.000583	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.24e-07	0.000562	CbGpPWpGaD
Lumiracoxib—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	1.22e-07	0.000552	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.14e-07	0.000517	CbGpPWpGaD
Lumiracoxib—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.08e-07	0.00049	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.04e-07	0.000471	CbGpPWpGaD
Lumiracoxib—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	1.02e-07	0.000462	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.79e-08	0.000444	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9e-08	0.000408	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.93e-08	0.000405	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.87e-08	0.000403	CbGpPWpGaD
Lumiracoxib—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.8e-08	0.000399	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.2e-08	0.000372	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.63e-08	0.000346	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	7.4e-08	0.000336	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.01e-08	0.000318	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	6.75e-08	0.000306	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	5.77e-08	0.000262	CbGpPWpGaD
Lumiracoxib—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.07e-08	0.00023	CbGpPWpGaD
Lumiracoxib—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.63e-08	0.00021	CbGpPWpGaD
Lumiracoxib—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.95e-08	0.000179	CbGpPWpGaD
